Therapeutic monoclonal antibody N-glycosylation – Structure, function and therapeutic potential

Biologicals

Volumn 52, Issue , 2018, Pages 1-11

  Cymer, Florian ^a   Beck, Hermann ^a   Rohde, Adelheid ^a   Reusch, Dietmar ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

ADCC; ADCP; CDC; Effector function; Fc receptors; Glycans; Glycosylation; IgG; Therapeutic antibodies

Indexed keywords

FC RECEPTOR; GLYCAN; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY;

ANALYTIC METHOD; ANTIBODY PRODUCTION; BINDING AFFINITY; BIOENGINEERING; CARBOHYDRATE ANALYSIS; CHEMICAL MODIFICATION; DRUG STRUCTURE; ENDOPLASMIC RETICULUM; ENZYME MODIFICATION; FUCOSYLATION; GALACTOSYLATION; GLYCOENGINEERING; GLYCOSYLATION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SEPARATION TECHNIQUE; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; PROTEIN PROCESSING;

ANIMALS; ANTIBODIES, MONOCLONAL; GLYCOSYLATION; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85035118047     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2017.11.001     Document Type: Review

References (149)

1. Reichert, J.M., Metrics for antibody therapeutics development. MAbs 2 (2010), 695–700.
2. Reichert, J.M., Rosensweig, C.J., Faden, L.B., Dewitz, M.C., Monoclonal antibody successes in the clinic. Nat Biotechnol 23 (2005), 1073–1078.
3. Reichert, J.M., Global antibody development trends. MAbs 1 (2009), 86–87.
4. Kabat, E.A., Wu, T., Perry, H., Gottesman, K., Foeller, C., Sequences of proteins of immunological interest. 91–3242, 1991, NIH Publication No. 91 3242.
5. Barnhart, B.C., Quigley, M., Role of Fc-FcgammaR interactions in the antitumor activity of therapeutic antibodies. Immunol Cell Biol 95 (2017), 340–346.
6. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002), 754–758.
7. Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26 (2008), 1789–1796.
8. Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27 (2009), 1122–1129.
9. Beck, A., Wagner-Rousset, E., Bussat, M.C., Lokteff, M., Klinguer-Hamour, C., Haeuw, J.F., et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 9 (2008), 482–501.
10. Robak, T., GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 10 (2009), 588–596.
11. Dalle, S., Reslan, L., Besseyre de Horts, T., Herveau, S., Herting, F., Plesa, A., et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 10 (2011), 178–185.
12. Kern, D.J., James, B.R., Blackwell, S., Gassner, C., Klein, C., Weiner, G.J., GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma 54 (2013), 2500–2505.
13. Golay, J., Da Roit, F., Bologna, L., Ferrara, C., Leusen, J.H., Rambaldi, A., et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122 (2013), 3482–3491.
14. Mossner, E., Brunker, P., Moser, S., Puntener, U., Schmidt, C., Herter, S., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115 (2010), 4393–4402.
15. Schwab, I., Nimmerjahn, F., Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat Rev Immunol 13 (2013), 176–189.
16. Anthony, R.M., Nimmerjahn, F., The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transpl 16 (2011), 7–14.
17. Kaneko, Y., Nimmerjahn, F., Ravetch, J.V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006), 670–673.
18. Samuelsson, A., Towers, T.L., Ravetch, J.V., Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001), 484–486.
19. Anthony, R.M., Wermeling, F., Karlsson, M.C., Ravetch, J.V., Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U. S. A 105 (2008), 19571–19578.
20. Nimmerjahn, F., Ravetch, J.V., The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204 (2007), 11–15.
21. Malaby, H.L., Kobertz, W.R., The middle X residue influences cotranslational N-glycosylation consensus site skipping. Biochemistry 53 (2014), 4884–4893.
22. Ellgaard, L., McCaul, N., Chatsisvili, A., Braakman, I., Co- and post-translational protein folding in the ER. Traffic 17 (2016), 615–638.
23. Tannous, A., Pisoni, G.B., Hebert, D.N., Molinari, M., N-linked sugar-regulated protein folding and quality control in the ER. Semin Cell Dev Biol 41 (2015), 79–89.
24. Zhang, X., Wang, Y., Glycosylation quality control by the Golgi structure. J Mol Biol 428 (2016), 3183–3193.
25. Luley-Goedl, C., Schmoelzer, K., Thomann, M., Malik, S., Greif, M., Ribitsch, D., et al. Two N-terminally truncated variants of human beta-galactoside alpha2,6 sialyltransferase I with distinct properties for in vitro protein glycosylation. Glycobiology 26 (2016), 1097–1106.
26. Kogelberg, H., Tolner, B., Sharma, S.K., Lowdell, M.W., Qureshi, U., Robson, M., et al. Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy. Glycobiology 17 (2007), 36–45.
27. Yang, J., Primack, R., Frohn, M., Wang, W., Luan, P., Retter, M.W., et al. Impact of glycation on antibody clearance. Aaps J 17 (2015), 237–244.
28. Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., et al. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs 4 (2012), 475–487.
29. Chen, X., Liu, Y.D., Flynn, G.C., The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 19 (2009), 240–249.
30. Aebi, M., N-linked protein glycosylation in the ER. Biochim Biophys Acta 1833 (2013), 2430–2437.
31. Chung, C.H., Mirakhur, B., Chan, E., Le, Q.T., Berlin, J., Morse, M., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 (2008), 1109–1117.
32. Hokke, C.H., Bergwerff, A.A., van Dedem, G.W., van Oostrum, J., Kamerling, J.P., Vliegenthart, J.F., Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett 275 (1990), 9–14.
33. Costa, A.R., Rodrigues, M.E., Henriques, M., Oliveira, R., Azeredo, J., Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol 34 (2014), 281–299.
34. del Val, I.J., Kontoravdi, C., Nagy, J.M., Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol Prog 26 (2010), 1505–1527.
35. Hossler, P., Khattak, S.F., Li, Z.J., Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19 (2009), 936–949.
36. Werner, R.G., Kopp, K., Schlueter, M., Glycosylation of therapeutic proteins in different production systems. Acta Paediatr 96 (2007), 17–22.
37. Le, N.P., Bowden, T.A., Struwe, W.B., Crispin, M., Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. Biochim Biophys Acta 1860 (2016), 1655–1668.
38. Dekkers, G., Plomp, R., Koeleman, C.A., Visser, R., von Horsten, H.H., Sandig, V., et al. Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. Sci Rep, 6, 2016, 36964.
39. Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278 (2003), 3466–3473.
40. Zhang, N., Liu, L., Dumitru, C.D., Cummings, N.R., Cukan, M., Jiang, Y., et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs 3 (2011), 289–298.
41. Ferrara, C., Brunker, P., Suter, T., Moser, S., Puntener, U., Umana, P., Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1. 4-N-acetylglucosaminyltransferase III Golgi alpha-mannosidase II Biotechnol Bioeng 93 (2006), 851–861.
42. Thomann, M., Schlothauer, T., Dashivets, T., Malik, S., Avenal, C., Bulau, P., et al. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PLoS One, 10, 2015, e0134949.
43. Kepert, J.F., Cromwell, M., Engler, N., Finkler, C., Gellermann, G., Gennaro, L., et al. Establishing a control system using QbD principles. Biologicals 44 (2016), 319–331.
44. Finkler, C., Krummen, L., Introduction to the application of QbD principles for the development of monoclonal antibodies. Biologicals 44 (2016), 282–290.
45. Huhn, C., Selman, M.H., Ruhaak, L.R., Deelder, A.M., Wuhrer, M., IgG glycosylation analysis. Proteomics 9 (2009), 882–913.
46. Marino, K., Bones, J., Kattla, J.J., Rudd, P.M., A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol 6 (2010), 713–723.
47. Pabst, M., Altmann, F., Glycan analysis by modern instrumental methods. Proteomics 11 (2011), 631–643.
48. Reusch, D., Haberger, M., Falck, D., Peter, B., Maier, B., Gassner, J., et al. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: mass spectrometric methods. MAbs 7 (2015), 732–742.
49. Reusch, D., Haberger, M., Maier, B., Maier, M., Kloseck, R., Zimmermann, B., et al. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles–part 1: separation-based methods. MAbs 7 (2015), 167–179.
50. Lynaugh, H., Li, H., Gong, B., Rapid Fc glycosylation analysis of Fc fusions with IdeS and liquid chromatography mass spectrometry. MAbs 5 (2013), 641–645.
51. Wang, B., Gucinski, A.C., Keire, D.A., Buhse, L.F., Boyne, M.T. 2nd, Structural comparison of two anti-CD20 monoclonal antibody drug products using middle-down mass spectrometry. Analyst 138 (2013), 3058–3065.
52. Zhang, Z., Pan, H., Chen, X., Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom Rev 28 (2009), 147–176.
53. Bones, J., Mittermayr, S., O'Donoghue, N., Guttman, A., Rudd, P.M., Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem 82 (2010), 10208–10215.
54. Guttman, A., Chen, F.T., Evangelista, R.A., Cooke, N., High-resolution capillary gel electrophoresis of reducing oligosaccharides labeled with 1-aminopyrene-3,6,8-trisulfonate. Anal Biochem 233 (1996), 234–242.
55. Reusch, D., Haberger, M., Kailich, T., Heidenreich, A.K., Kampe, M., Bulau, P., et al. High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel electrophoresis using a DNA analyzer. MAbs 6 (2014), 185–196.
56. Bruggink, C., Maurer, R., Herrmann, H., Cavalli, S., Hoefler, F., Analysis of carbohydrates by anion exchange chromatography and mass spectrometry. J Chromatogr A 1085 (2005), 104–109.
57. de Haan, N., Reiding, K.R., Haberger, M., Reusch, D., Falck, D., Wuhrer, M., Linkage-specific sialic acid derivatization for MALDI-TOF-MS profiling of IgG glycopeptides. Anal Chem 87 (2015), 8284–8291.
58. Selman, M.H., McDonnell, L.A., Palmblad, M., Ruhaak, L.R., Deelder, A.M., Wuhrer, M., Immunoglobulin G glycopeptide profiling by matrix-assisted laser desorption ionization Fourier transform ion cyclotron resonance mass spectrometry. Anal Chem 82 (2010), 1073–1081.
59. Reusch, D., Haberger, M., Selman, M.H., Bulau, P., Deelder, A.M., Wuhrer, M., et al. High-throughput work flow for IgG Fc-glycosylation analysis of biotechnological samples. Anal Biochem 432 (2013), 82–89.
60. Cheng, H.L., Pai, P.J., Her, G.R., Linkage and branch determination of N-linked oligosaccharides using sequential degradation/closed-ring chromophore labeling/negative ion trap mass spectrometry. J Am Soc Mass Spectrom 18 (2007), 248–259.
61. Domann, P., Spencer, D.I., Harvey, D.J., Production and fragmentation of negative ions from neutral N-linked carbohydrates ionized by matrix-assisted laser desorption/ionization. Rapid Commun Mass Spectrom 26 (2012), 469–479.
62. Lin, Z., Lubman, D.M., Permethylated N-glycan analysis with mass spectrometry. Methods Mol Biol 1007 (2013), 289–300.
63. Zhou, S., Hu, Y., DeSantos-Garcia, J.L., Mechref, Y., Quantitation of permethylated N-glycans through multiple-reaction monitoring (MRM) LC-MS/MS. J Am Soc Mass Spectrom 26 (2015), 596–603.
64. Yamaguchi, Y., Nishimura, M., Nagano, M., Yagi, H., Sasakawa, H., Uchida, K., et al. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta 1760 (2006), 693–700.
65. Barb, A.W., Prestegard, J.H., NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol 7 (2011), 147–153.
66. Ferrara, C., Grau, S., Jager, C., Sondermann, P., Brunker, P., Waldhauer, I., et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U. S. A 108 (2011), 12669–12674.
67. Subedi, G.P., Barb, A.W., The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc gamma receptor. MAbs, 2016, 1–13.
68. Frank, M., Walker, R.C., Lanzilotta, W.N., Prestegard, J.H., Barb, A.W., Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J Mol Biol 426 (2014), 1799–1811.
69. Barb, A.W., Meng, L., Gao, Z., Johnson, R.W., Moremen, K.W., Prestegard, J.H., NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry 51 (2012), 4618–4626.
70. Subedi Ganesh, P., Hanson Quinlin, M., Barb Adam, W., Restricted motion of the conserved immunoglobulin g1 N-glycan is essential for efficient FcγRIIIa binding. Structure 22 (2014), 1478–1488.
71. Buck, P.M., Kumar, S., Singh, S.K., Consequences of glycan truncation on Fc structural integrity. MAbs 5 (2013), 904–916.
72. Chen, W., Kong, L., Connelly, S., Dendle, J.M., Liu, Y., Wilson, I.A., et al. Stabilizing the CH2 domain of an antibody by engineering in an enhanced aromatic sequon. ACS Chem Biol 11 (2016), 1852–1861.
73. Zheng, K., Yarmarkovich, M., Bantog, C., Bayer, R., Patapoff, T.W., Influence of glycosylation pattern on the molecular properties of monoclonal antibodies. MAbs 6 (2014), 649–658.
74. Dalziel, M., Crispin, M., Scanlan, C.N., Zitzmann, N., Dwek, R.A., Emerging principles for the therapeutic exploitation of glycosylation. Science, 343, 2014, 1235681.
75. Crispin, M., Yu, X., Bowden, T.A., Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc Natl Acad Sci U. S. A 110 (2013), E3544–E3546.
76. Anthony, R.M., Ravetch, J.V., A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 30:1 (2010), S9–S14.
77. Jiang, X.R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10 (2011), 101–111.
78. Read, E.K., Park, J.T., Brorson, K.A., Industry and regulatory experience of the glycosylation of monoclonal antibodies. Biotechnol Appl Biochem 58 (2011), 213–219.
79. Liu, H., Gaza-Bulseco, G., Faldu, D., Chumsae, C., Sun, J., Heterogeneity of monoclonal antibodies. J Pharm Sci 97 (2008), 2426–2447.
80. Liu, D., Ren, D., Huang, H., Dankberg, J., Rosenfeld, R., Cocco, M.J., et al. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 47 (2008), 5088–5100.
81. Harris, R.J., Kabakoff, B., Macchi, F.D., Shen, F.J., Kwong, M., Andya, J.D., et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752 (2001), 233–245.
82. Shields, R.L., Namenuk, A.K., Hong, K., Meng, Y.G., Rae, J., Briggs, J., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276 (2001), 6591–6604.
83. Quan, C., Alcala, E., Petkovska, I., Matthews, D., Canova-Davis, E., Taticek, R., et al. A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior. Anal Biochem 373 (2008), 179–191.
84. Cosgrave, E.F., Struwe, W.B., Hayes, J.M., Harvey, D.J., Wormald, M.R., Rudd, P.M., N-linked glycan structures of the human Fcgamma receptors produced in NS0 cells. J Proteome Res 12 (2013), 3721–3737.
85. Zeck, A., Pohlentz, G., Schlothauer, T., Peter-Katalinic, J., Regula, J.T., Cell type-specific and site directed N-glycosylation pattern of FcgammaRIIIa. J Proteome Res 10 (2011), 3031–3039.
86. Hayes, J.M., Frostell, A., Karlsson, R., Muller, S., Martin, S.M., Pauers, M., et al. Identification of Fc gamma receptor glycoforms that produce differential binding kinetics for rituximab. Mol Cell Proteomics 16 (2017), 1770–1788.
87. Biburger, M., Lux, A., Nimmerjahn, F., How Immunoglobulin G Antibodies Kill Target Cells 124 (2014), 67–94.
88. Merle, N.S., Church, S.E., Fremeaux-Bacchi, V., Roumenina, L.T., Complement system Part I - molecular mechanisms of activation and regulation. Front Immunol, 6, 2015, 262.
89. Pyzik, M., Rath, T., Lencer, W.I., Baker, K., Blumberg, R.S., FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. J Immunol 194 (2015), 4595–4603.
90. Jung, S.T., Reddy, S.T., Kang, T.H., Borrok, M.J., Sandlie, I., Tucker, P.W., et al. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U. S. A 107 (2010), 604–609.
91. Liu, L., Stadheim, A., Hamuro, L., Pittman, T., Wang, W., Zha, D., et al. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials. Biologicals 39 (2011), 205–210.
92. Leabman, M.K., Meng, Y.G., Kelley, R.F., DeForge, L.E., Cowan, K.J., Iyer, S., Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs 5 (2013), 896–903.
93. Souders, C.A., Nelson, S.C., Wang, Y., Crowley, A.R., Klempner, M.S., Thomas, W. Jr., A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs 7 (2015), 912–921.
94. Liu, L., Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci 104 (2015), 1866–1884.
95. Edberg, J.C., Kimberly, R.P., Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding. J Immunol 159 (1997), 3849–3857.
96. Sazinsky, S.L., Ott, R.G., Silver, N.W., Tidor, B., Ravetch, J.V., Wittrup, K.D., Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U. S. A 105 (2008), 20167–20172.
97. Jung, S.T., Kelton, W., Kang, T.H., Ng, D.T., Andersen, J.T., Sandlie, I., et al. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcgammaRIIa affinity and selectivity. ACS Chem Biol 8 (2013), 368–375.
98. Ju, M.S., Jung, S.T., Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics. Curr Opin Biotechnol 30C (2014), 128–139.
99. Yu, X., Vasiljevic, S., Mitchell, D.A., Crispin, M., Scanlan, C.N., Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol 425 (2013), 1253–1258.
100. Lund, J., Takahashi, N., Pound, J.D., Goodall, M., Jefferis, R., Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 157 (1996), 4963–4969.
101. Boyd, P.N., Lines, A.C., Patel, A.K., The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 32 (1995), 1311–1318.
102. Vafa, O., Gilliland, G.L., Brezski, R.J., Strake, B., Wilkinson, T., Lacy, E.R., et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 65 (2014), 114–126.
103. Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S.P., Goodall, M., et al. Role of oligosaccharide residues of IgG1-fc in Fc RIIb binding. J Biol Chem 276 (2001), 45539–45547.
104. Karagiannis, S.N., Dashivets, T., Thomann, M., Rueger, P., Knaupp, A., Buchner, J., et al. Multi-angle effector function analysis of human monoclonal IgG glycovariants. PLoS One, 10, 2015, e0143520.
105. Leabman, M.K., Meng, Y.G., Kelley, R.F., DeForge, L.E., Cowan, K.J., Iyer, S., Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs 5 (2014), 896–903.
106. Jensen, P.F., Larraillet, V., Schlothauer, T., Kettenberger, H., Hilger, M., Rand, K.D., Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry. Mol Cell Proteomics 14 (2015), 148–161.
107. Niwa, R., Natsume, A., Uehara, A., Wakitani, M., Iida, S., Uchida, K., et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 306 (2005), 151–160.
108. Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17 (2007), 104–118.
109. Mimoto, F., Kadono, S., Katada, H., Igawa, T., Kamikawa, T., Hattori, K., Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcgammaRs. Mol Immunol 58 (2014), 132–138.
110. Zhou, Q., Shankara, S., Roy, A., Qiu, H., Estes, S., McVie-Wylie, A., et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99 (2008), 652–665.
111. Mimoto, F., Igawa, T., Kuramochi, T., Katada, H., Kadono, S., Kamikawa, T., et al. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant. MAbs 5 (2014), 229–236.
112. Mimoto, F., Kadono, S., Katada, H., Igawa, T., Kamikawa, T., Hattori, K., Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. Mol Immunol 58 (2014), 132–138.
113. Nimmerjahn, F., Anthony, R.M., Ravetch, J.V., Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U. S. A 104 (2007), 8433–8437.
114. Hodoniczky, J., Zheng, Y.Z., James, D.C., Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 21 (2005), 1644–1652.
115. Karsten, C.M., Pandey, M.K., Figge, J., Kilchenstein, R., Taylor, P.R., Rosas, M., et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 18 (2012), 1401–1406.
116. Houde, D., Peng, Y., Berkowitz, S.A., Engen, J.R., Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 9 (2010), 1716–1728.
117. Thomann, M., Reckermann, K., Reusch, D., Prasser, J., Tejada, M.L., Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol 73 (2016), 69–75.
118. Quast, I., Keller, C.W., Maurer, M.A., Giddens, J.P., Tackenberg, B., Wang, L.X., et al. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest 125 (2015), 4160–4170.
119. Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S.P., Goodall, M., et al. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem 276 (2001), 45539–45547.
120. Mimoto, F., Igawa, T., Kuramochi, T., Katada, H., Kadono, S., Kamikawa, T., et al. Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant. MAbs 5 (2013), 229–236.
121. Dekkers, G., Treffers, L., Plomp, R., Bentlage, A.E.H., de Boer, M., Koeleman, C.A.M., et al. Decoding the human immunoglobulin g-glycan repertoire reveals a spectrum of fc-receptor- and complement-mediated-effector activities. Front Immunol, 8, 2017, 877.
122. Schnueriger, A., Grau, R., Sondermann, P., Schreitmueller, T., Marti, S., Zocher, M., Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol Immunol 48 (2011), 1512–1517.
123. Miller, A.S., Tejada, M.L., Gazzano-Santoro, H., Methods for measuring antibody-dependent cell-mediated cytotoxicity in vitro. Methods Mol Biol 1134 (2014), 59–65.
124. Hayes, J.M., Frostell, A., Cosgrave, E.F., Struwe, W.B., Potter, O., Davey, G.P., et al. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions. J Proteome Res 13 (2014), 5471–5485.
125. Mellor, J.D., Brown, M.P., Irving, H.R., Zalcberg, J.R., Dobrovic, A., A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol, 6(1), 2013.
126. Nimmerjahn, F., Ravetch, J.V., Fcgamma receptors: old friends and new family members. Immunity 24 (2006), 19–28.
127. Nimmerjahn, F., Ravetch, J.V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005), 1510–1512.
128. Armour, K.L., Smith, C.S., Clark, M.R., Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding. J Immunol Methods 354 (2010), 20–33.
129. Kao, D., Danzer, H., Collin, M., Groß A., Eichler, J., Stambuk, J., et al. A monosaccharide residue is sufficient to maintain mouse and human IgG subclass activity and directs IgG effector functions to cellular Fc receptors. Cell Rep 13 (2015), 2376–2385.
130. Nimmerjahn, F., Ravetch, J.V., Analyzing antibody-Fc-receptor interactions. Methods Mol Biol 415 (2008), 151–162.
131. Lux, A., Yu, X., Scanlan, C.N., Nimmerjahn, F., Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol 190 (2013), 4315–4323.
132. Barel, M., Frade, R., Detection of Fc gamma receptors on human lymphoblastoid cell surfaces using a simple solid phase radioimmunoassay specific for human IgG. J Immunol Methods 37 (1980), 123–131.
133. Okazaki, A., Shoji-Hosaka, E., Nakamura, K., Wakitani, M., Uchida, K., Kakita, S., et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 336 (2004), 1239–1249.
134. Davidoff, S.N., Ditto, N.T., Brooks, A.E., Eckman, J., Brooks, B.D., Surface plasmon resonance for therapeutic antibody characterization. Fang, Y., (eds.) Label-free biosensor methods in drug discovery, 2015, Springer New York, New York, NY, 35–76.
135. Wang, X., McKay, P., Yee, L.T., Dutina, G., Hass, P.E., Nijem, I., et al. Impact of SPR biosensor assay configuration on antibody: neonatal Fc receptor binding data. MAbs 9 (2017), 319–332.
136. Abdiche, Y.N., Yeung, Y.A., Chaparro-Riggers, J., Barman, I., Strop, P., Chin, S.M., et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs 7 (2015), 331–343.
137. Stracke, J., Emrich, T., Rueger, P., Schlothauer, T., Kling, L., Knaupp, A., et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. MAbs 6 (2014), 1229–1242.
138. Schlothauer, T., Rueger, P., Stracke, J.O., Hertenberger, H., Fingas, F., Kling, L., et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs 5 (2013), 576–586.
139. Schlothauer, T., Herter, S., Koller, C.F., Grau-Richards, S., Steinhart, V., Spick, C., et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel 29 (2016), 457–466.
140. Grau RM, S., Schnueringer, A., Sondermann, P., ADCC with modified NK92 cells. Office ep, 2010.
141. Mathur, A., Arora, T., Liu, L., Crouse-Zeineddini, J., Mukku, V., Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics. J Immunol Methods 390 (2013), 81–91.
142. Lux, A., Nimmerjahn, F., Impact of differential glycosylation on IgG activity. Adv Exp Med Biol 780 (2011), 113–124.
143. Dwek, R.A., Biological importance of glycosylation. Dev Biol Stand 96 (1998), 43–47.
144. Chen, G., Wang, Y., Qiu, L., Qin, X., Liu, H., Wang, X., et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J Proteomics 75 (2012), 2824–2834.
145. Freidin, M.B., Keser, T., Gudelj, I., Stambuk, J., Vucenovic, D., Allegri, M., et al. The association between low back pain and composition of IgG glycome. Sci Rep, 6, 2016, 26815.
146. Xu, H., Guo, H., Cheung, I.Y., Cheung, N.K., Antitumor efficacy of anti-GD2 IgG1 is enhanced by Fc glyco-engineering. Cancer Immunol Res 4 (2016), 631–638.
147. Zuercher, A.W., Spirig, R., Baz Morelli, A., Kasermann, F., IVIG in autoimmune disease - potential next generation biologics. Autoimmun Rev 15 (2016), 781–785.
148. Gray, C.J., Thomas, B., Upton, R., Migas, L.G., Eyers, C.E., Barran, P.E., et al. Applications of ion mobility mass spectrometry for high throughput, high resolution glycan analysis. Biochim Biophys Acta 1860 (2016), 1688–1709.
149. Reatini, B.S., Ensink, E., Liau, B., Sinha, J.Y., Powers, T.W., Partyka, K., et al. Characterizing protein glycosylation through on-chip glycan modification and probing. Anal Chem 88 (2016), 11584–11592.